Senator Bernie Sanders wants to meet next week with Novo Nordisk A/S’s top executive about lowering the price of its blockbuster drug Ozempic, fueling controversy over the costs of GLP-1 drugs for diabetes and obesity.
(Bloomberg) — Senator Bernie Sanders wants to meet next week with Novo Nordisk A/S’s top executive about lowering the price of its blockbuster drug Ozempic, fueling controversy over the costs of GLP-1 drugs for diabetes and obesity. Read More
Related
Share this page
Guest Posts by Easy Branches
